过去一年中添加的文章，按日期排序
Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Y Wang, Q Yin, J Ren, H Zhou, T Gong, F Zhu, X Zhang… - 2024 - ascopubs.org
34 天前 - … Conclusions: Preliminary data show CN201 has a well tolerable safety profile and
promising activity in adult patients with relapsed or refractory ALL. Clinical trial information: …
promising activity in adult patients with relapsed or refractory ALL. Clinical trial information: …
A phase IIA clinical trial to evaluate a reversible Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non …
N Lee, Y Li, Y Mao, G Liu, J Li, Q Liu - 2024 - ascopubs.org
34 天前 - … is based on iwCLL 2018 guidelines for chronic lymphocytic leukemia (CLL), IWWM-7
… for all other lymphomas, including small lymphocytic lymphoma (SLL), diffuse large B-cell …
… for all other lymphomas, including small lymphocytic lymphoma (SLL), diffuse large B-cell …
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure
F Despas, M Chaouki, S de Barros… - Leukemia & …, 2024 - Taylor & Francis
49 天前 - … Notably, clinical trials involving relapsed indolent non-Hodgkin lymphomas (iNHL)
and chronic/small lymphocytic leukemia (CLL/SLL) which used idelalisib either as a …
and chronic/small lymphocytic leukemia (CLL/SLL) which used idelalisib either as a …
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL
54 天前 - … B cell chronic lymphocytic leukemia (B-CLL) is a common leukemia subtype [1]
and … However, NK cells are frequently dysfunctional in patients with cancer, and this profile …
and … However, NK cells are frequently dysfunctional in patients with cancer, and this profile …
Abstract CT147: Phase I clinical study of Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin …
N Lee, Y Li, Y Mao, G Liu, J Li, Q Liu - Cancer Research, 2024 - AACR
88 天前 - … 21 patients underwent at least 1 response assessment (4 chronic lymphocytic
leukemia (CLL)/small lymphocytic lymphoma (SLL); 4 marginal zone lymphoma (MZL); 5 mantle …
leukemia (CLL)/small lymphocytic lymphoma (SLL); 4 marginal zone lymphoma (MZL); 5 mantle …
[PDF][PDF] Who's on First, What's on Second? Clinical Conundrums in Chronic Lymphocytic Leukemia
D Mansour, SK Yingling - HOPA, 2024 - hoparx.org
104 天前 - … + chlorambucil in treatment-naïve chronic lymphocytic leukemia: five-year follow-up
of … rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (…
of … rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (…
Serum IgG and IgA level in children with acute lymphoblastic leukaemia and its relation with outcome in induction chemotherapy
S Nahar, MA Karim, ATMA Rahman… - Haematology …, 2024 - journal.hematologybd.org
133 天前 - … sample size and more standardized clinical trials are required to verify the serum
immunoglobulin levels in children with acute lymphoblastic leukaemia and its relationship with …
immunoglobulin levels in children with acute lymphoblastic leukaemia and its relationship with …
Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency
M Migliavacca, F Barzaghi, C Fossati, PMV Rancoita… - Nature medicine, 2024 - nature.com
139 天前 - … approach for ADA-SCID, but long-term data are warranted. Here we report an
analysis on long-term safety and efficacy data of 43 patients with ADA-SCID who received …
analysis on long-term safety and efficacy data of 43 patients with ADA-SCID who received …
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort
EA Martino, FR Mauro, G Reda, L Laurenti… - Hematological …, 2024 - Wiley Online Library
159 天前 - … Chronic lymphocytic leukemia (CLL), the most prevalent hematologic neoplasm in
… Indeed, the majority of patients are over the age of 65 years at diagnosis, and the incidence …
… Indeed, the majority of patients are over the age of 65 years at diagnosis, and the incidence …
Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory Richter's transformation
CY Cheah, S Assouline, R Baker, NL Bartlett… - Blood, 2023 - Elsevier
217 天前 - … by the development of chronic lymphocytic leukemia to an aggressive lymphoma,
most commonly CD20+ large B-cell lymphoma. RT remains an unmet medical need with a …
most commonly CD20+ large B-cell lymphoma. RT remains an unmet medical need with a …